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The correlation between the level of immune involvement
and immune cell infiltration within a treated tumour and
the clinical outcome for patients has been well established
in many solid tumour types. High numbers of tumour
infiltrating lymphocytes has been associated with a signifi-
cantly improved prognosis. Some of the key cell types
involved are CD3+and CD8+ T cells, B cells and APCs
such as dendritic cells (DCs).
Cork Cancer Research Centre (CCRC) has long utilised
an ablative cancer treatment that involves delivering a
pulse of electrical energy (electroporation) directly to the
tumour. This treatment results in the formation of reversi-
ble pores in the cell membrane, allowing up to a 1000 fold
increase in chemotherapy drug absorption (Electroche-
motherapy). A significant benefit of this non thermal
ablation is the release of tumour associated antigens into
the microenvironment, leading to activation of APCs and
subsequent cross presentation of the antigens to circulat-
ing T and B cells. While ECT facilitates the priming of a
favourable immune response, the combination of iCOS
antibody, capable of stimulating T cell proliferation, causes
a very robust mediated regression of treated tumours.
In addition, ICOS is involved in humoral immune
responses (B cell germinal center formation) and increases
the production of IL-4.
Preclinical work in aggressive murine models has yielded
very encouraging results. The combinational therapy has
achieved cures in both colorectal (CT26) and metastatic
lung (LLC) cancer cell lines. Follow up immunohisto-
chemical staining confirmed the presence of tumour
infiltrating CD3+ and CD8+ T cells, CD45R+ B cells and
CD11c+ DCs, post treatment.
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